DBV Technologies (NASDAQ:DBVT) Research Coverage Started at StockNews.com

StockNews.com assumed coverage on shares of DBV Technologies (NASDAQ:DBVT) in a research report report published on Tuesday morning. The firm issued a hold rating on the stock.

Several other research firms also recently commented on DBVT. JMP Securities reiterated a “market outperform” rating and issued a $5.00 price objective on shares of DBV Technologies in a report on Tuesday, September 24th. HC Wainwright lifted their price target on DBV Technologies from $5.00 to $7.00 and gave the stock a “buy” rating in a research note on Thursday, October 24th.

DBV Technologies Price Performance

NASDAQ:DBVT opened at $0.78 on Tuesday. DBV Technologies has a 1-year low of $0.50 and a 1-year high of $2.17. The business has a 50 day moving average of $0.76 and a 200 day moving average of $0.94. The company has a market capitalization of $75.11 million, a price-to-earnings ratio of -0.93 and a beta of 0.67.

DBV Technologies (NASDAQ:DBVT) last released its earnings results on Tuesday, July 30th. The company reported ($0.34) EPS for the quarter, missing the consensus estimate of ($0.26) by ($0.08). The business had revenue of $1.16 million for the quarter, compared to the consensus estimate of $1.42 million. DBV Technologies had a negative net margin of 638.21% and a negative return on equity of 74.41%. During the same period in the prior year, the business posted ($0.26) EPS. As a group, sell-side analysts anticipate that DBV Technologies will post -1.43 EPS for the current year.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in DBV Technologies stock. Yiheng Capital Management L.P. grew its holdings in shares of DBV Technologies S.A. (NASDAQ:DBVT) by 6.2% during the 1st quarter, according to its most recent Form 13F filing with the SEC. The firm owned 5,568,909 shares of the company’s stock after buying an additional 327,345 shares during the period. DBV Technologies accounts for 0.2% of Yiheng Capital Management L.P.’s portfolio, making the stock its 15th biggest position. Yiheng Capital Management L.P. owned approximately 2.89% of DBV Technologies worth $4,172,000 as of its most recent SEC filing. 71.74% of the stock is owned by hedge funds and other institutional investors.

About DBV Technologies

DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow’s milk protein allergy and eosinophilic esophagitis.